Sermorelin Injection is a prescription therapy used for growth hormone support.

Patients seeking support for growth hormone support may qualify after evaluation by a licensed provider.

Yes. Sermorelin is a compounded prescription peptide requiring a valid prescription from a licensed healthcare provider. A baseline evaluation — including IGF-1, fasting glucose, and thyroid panel — is required before prescribing, along with a telehealth consultation and full medical intake to confirm candidacy, screen for contraindications, and establish an individualized protocol.

Sermorelin is generally well tolerated at therapeutic doses. The most common side effect is injection site reactions — redness, swelling, or transient pain at the site. Additional reported effects include facial flushing or warmth shortly after injection, headache, dizziness, occasional nausea, mild fluid retention or peripheral edema (particularly early in treatment), somnolence consistent with bedtime dosing, and transient increases in fasting glucose. Report all new or worsening symptoms to your provider promptly.

Sermorelin is contraindicated in patients with active malignancy or a history of GH/IGF-1-sensitive cancers (including certain breast, prostate, and colorectal cancers) — oncology consultation is required for any cancer history. Patients with untreated hypothyroidism, elevated baseline IGF-1, active intracranial lesions, pituitary tumors, or recent neurosurgery are not appropriate candidates. Those with diabetes or significant insulin resistance require careful monitoring and medication coordination. It is not appropriate for patients who are pregnant, breastfeeding, or under 18.

Glucocorticoids suppress GH secretion and blunt pituitary response to GHRH — patients on corticosteroid therapy may experience reduced sermorelin efficacy and should discuss this with their provider. Somatostatin analogs (octreotide, lanreotide) directly antagonize sermorelin's mechanism at the pituitary and are contraindicated with concurrent use. Patients on insulin or antidiabetic agents may need adjustments as sermorelin-stimulated GH can reduce insulin sensitivity. Other GH secretagogues (ipamorelin, CJC-1295) are frequently combined with sermorelin for synergistic effect and require provider oversight and appropriate dose adjustments.

Patients with any history of malignancy — particularly GH/IGF-1-sensitive cancers — require oncology consultation before initiating sermorelin. Those with diabetes, significant cardiovascular disease, hypothyroidism, or intracranial conditions require careful individualized evaluation. Regular monitoring of IGF-1, fasting glucose, and relevant metabolic parameters is standard of care throughout treatment. Your provider will determine the appropriate protocol based on your baseline labs and complete medical history.